Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caloxetic Acid Free Base SCHEMBL19667947 | 1.00 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| Caloxetic Acid Free Base SCHEMBL8412091 | 0.99 | MAOB (0.43) | MAOBALOX5ACACBALDH1A1POLB | |
| Caloxetic Acid Free Base SCHEMBL92689 | 0.99 | MAOB (0.43) | MAOBALOX5ACACBALDH1A1POLB | |
| Caloxetic Acid Free Base SCHEMBL29375456 | 0.98 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21327620 | 0.95 | MAOB (0.41) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21327618 | 0.95 | MAOB (0.41) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21919169 | 0.94 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21919234 | 0.93 | MAOB (0.41) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL8672662 | 0.93 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL8341415 | 0.93 | MAOB (0.46) | MAOBALOX5ACACBALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464237-B1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2023-12-20 | — | — | EP | claimed |
| US-11149041-B2 | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2021-10-19 | — | — | US | claimed |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2020-04-23 | — | — | US | claimed |
| EP-3464237-A1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2019-04-10 | — | — | EP | claimed |
| EP-3464237-B1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2023-12-20 | — | — | EP | disclosed |
| EP-3464237-B1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2023-12-20 | — | — | EP | disclosed |
| US-11149041-B2 | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2021-10-19 | — | — | US | disclosed |
| US-11149041-B2 | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2021-10-19 | — | — | US | disclosed |
| US-11149041-B2 | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2021-10-19 | — | — | US | disclosed |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2020-04-23 | — | — | US | disclosed |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2020-04-23 | — | — | US | disclosed |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2020-04-23 | — | — | US | disclosed |
| EP-3464237-A4 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2020-02-19 | — | — | EP | disclosed |
| EP-3464237-A1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464237-A1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464237-A1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017208258-A1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017208258-A1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149041-B2 | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | CA9, CA4, GLRX3 | MAOB 1419/4885ALOX5 3249/4885ACACB 3057/4885 |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | GLRX3, CA9, CA4 | MAOB 1325/4885ALOX5 2520/4885ACACB 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.